Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: Provided is the use of an insulin-like growth factor-2 for preparing a pharmaceutical composition, wherein the pharmaceutical composition is used for (i) promoting the expression of the macrophage PD-L1, and/or (ii) inhibiting the expression of the macrophage IL-?. Also provided is a pharmaceutical composition containing insulin-like growth factor-2 as an active ingredient.

Abstract: The use of a muscle stem cell in the preparation of a drug for preventing, alleviating and treating metabolic disorders, and a pharmaceutical composition for humans and animals, wherein the pharmaceutical composition comprises the muscle stem cell as a first active ingredient, a second active ingredient for regulating the glucose metabolism, and a pharmaceutically acceptable carrier.

Abstract: Provided is an application of a non-IGF1R-binding substance in the prevention and/or treatment of inflammatory diseases. Specifically, provided is use of a non-IGF1R-binding substance. The non-IGF1R-binding substance is used for preparing a composition or formulation, and the composition or formulation is used for preventing and/or treating inflammatory diseases.

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: Provided is an application of an ICAM-1 marker and a regulating agent thereof in promoting or inhibiting differentiation of adipose-derived stem cells into adipose cells, and an application of ICAM-1 or detection reagent thereof in (a) detecting adipose-derived stem cells, and/or (b) determining the risk of a subject suffering from obesity and a corresponding diagnostic kit and method. Further provided is an in vitro non-therapeutic preparation method for fat cells.

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: Provided is the use of an insulin-like growth factor-2 for preparing a pharmaceutical composition, wherein the pharmaceutical composition is used for (i) promoting the expression of the macrophage PD-L1, and/or (ii) inhibiting the expression of the macrophage IL-10. Also provided is a pharmaceutical composition containing insulin-like growth factor-2 as an active ingredient.

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: The present invention discloses the application of mesenchymal stem cells in the prophylaxis or treatment of stress response-induced weakened immunity. More particularly, the present invention provides the use of mesenchymal stem cells in preparing a pharmaceutical composition for the prophylaxis or treatment of stress response-induced lymphopenia; and/or the use thereof in preparing a pharmaceutical composition for the prophylaxis or treatment of stress response-induced weakened immunity; and/or the use thereof in preparing a pharmaceutical composition for the promotion of interleukin 4 (IL-4) expression and/or enhanced or strengthened activity. The present invention has found that mesenchymal stem cells can, by means of regulating IL-4 and down-stream related signaling pathways, protect against hormonal disorder-induced lymphopenia, thus having the function of activating immune response.

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: The present invention relates to a hypoxia-treated mesenchymal stem cell and the use thereof. The present invention discloses for the first time that treating mesenchymal stem cells with hypoxia can significantly promote alleviating or therapeutic effects of mesenchymal stem cells on inflammatory diseases. The present invention also discloses that the hypoxia-treated mesenchymal stem cell is capable of producing insulin-like growth factor-2, which plays a central role in the treatment of inflammatory diseases with the hypoxia-treated mesenchymal stem cell.

Abstract: The present invention discloses the application of mesenchymal stem cells in the prophylaxis or treatment of stress response-induced weakened immunity. More particularly, the present invention provides the use of mesenchymal stem cells in preparing a pharmaceutical composition for the prophylaxis or treatment of stress response-induced lymphopenia; and/or the use thereof in preparing a pharmaceutical composition for the prophylaxis or treatment of stress response-induced weakened immunity; and/or the use thereof in preparing a pharmaceutical composition for the promotion of interleukin 4 (IL-4) expression and/or enhanced or strengthened activity. The present invention has found that mesenchymal stem cells can, by means of regulating IL-4 and down-stream related signaling pathways, protect against hormonal disorder-induced lymphopenia, thus having the function of activating immune response.

Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).

Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).

Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).